Starting children on an insulin pump within 6 months of type 1 diabetes diagnosis is associated with improved outcomes relative to delaying for 2 or 3 years, shows an analysis of data from the DPV registry.
Children with type 1 diabetes make more consistent use of continuous glucose monitoring if they are given the device when they initiate insulin pump therapy, rather than several months later, show the CGM TIME Trial results.
Children with type 1 diabetes who use the Tandem Control-IQ hybrid closed-loop insulin delivery system spend more time with their blood glucose levels in the target range than those using a sensor-augmented insulin pump, show findings from the iDCL trial.
Canakinumab monotherapy tapering, either through dose reduction or dose interval prolongation, is feasible in children with systemic juvenile idiopathic arthritis who achieve clinical remission, study findings indicate.
Tanuja Chitnis tells us about the TERIKIDS study showing a numerical reduction in clinical relapse risk and a significant reduction in time to clinical relapse with teriflunomide in paediatric patients with relapsing-remitting multiple sclerosis (5:29).
Earlier age at menarche is associated with an increased risk for type 2 diabetes and impaired glucose tolerance among women, and this association remains significant after adjustment for adiposity, suggest findings from a meta-analysis.
Adalimumab, used with or without concurrent methotrexate, appears to be well tolerated among children with polyarticular‐course juvenile idiopathic arthritis, 7-year data from the STRIVE registry show.
Continuous glucose monitoring offers many benefits to the families of young children with type 1 diabetes but also a number of challenges that cannot always be overcome, show results of a qualitative analysis conducted in the USA.
Jonathan Santoro summarises their research evaluating disability distribution in paediatric-onset multiple sclerosis using a novel scoring model, and discusses the implications for the care of patients (4:31).
Early findings point to the antitumor efficacy of the next-generation TRK inhibitor LOXO-195 in patients with NTRK fusion-positive cancers and NTRK resistance mutations acquired during treatment with first-generation agents.